Analysts expect Vitamin Shoppe, Inc (NYSE:VSI) to post $296.71 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Vitamin Shoppe’s earnings. The highest sales estimate is $296.94 million and the lowest is $296.47 million. Vitamin Shoppe posted sales of $314.89 million during the same quarter last year, which suggests a negative year-over-year growth rate of 5.8%. The business is scheduled to report its next quarterly earnings report on Wednesday, November 1st.
According to Zacks, analysts expect that Vitamin Shoppe will report full-year sales of $296.71 million for the current financial year, with estimates ranging from $1.18 billion to $1.22 billion. For the next fiscal year, analysts anticipate that the business will report sales of $1.18 billion per share. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Vitamin Shoppe.
Vitamin Shoppe (NYSE:VSI) last announced its quarterly earnings results on Wednesday, August 9th. The specialty retailer reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.39 by ($0.16). The company had revenue of $304.84 million for the quarter, compared to analyst estimates of $314.74 million. Vitamin Shoppe had a positive return on equity of 8.33% and a negative net margin of 11.98%. The firm’s quarterly revenue was down 8.4% on a year-over-year basis. During the same quarter last year, the company posted $0.55 earnings per share.
Several analysts have recently weighed in on VSI shares. Zacks Investment Research upgraded shares of Vitamin Shoppe from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine cut shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Bank of America Corporation restated an “underperform” rating and set a $5.00 price objective (down previously from $5.50) on shares of Vitamin Shoppe in a research report on Wednesday, August 23rd. BidaskClub cut shares of Vitamin Shoppe from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Finally, Morgan Stanley restated an “equal weight” rating and set a $7.50 price objective (down previously from $8.00) on shares of Vitamin Shoppe in a research report on Monday, October 2nd. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. Vitamin Shoppe currently has an average rating of “Hold” and an average price target of $9.92.
Vitamin Shoppe (VSI) opened at 5.20 on Wednesday. Vitamin Shoppe has a one year low of $4.95 and a one year high of $28.41. The stock’s 50 day moving average is $5.40 and its 200 day moving average is $11.25. The firm’s market capitalization is $120.76 million.
In other Vitamin Shoppe news, Director John D. Bowlin bought 40,000 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The shares were bought at an average price of $5.50 per share, for a total transaction of $220,000.00. Following the transaction, the director now directly owns 56,028 shares in the company, valued at $308,154. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.07% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA raised its position in Vitamin Shoppe by 2.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the specialty retailer’s stock worth $108,000 after purchasing an additional 192 shares during the period. Municipal Employees Retirement System of Michigan raised its position in Vitamin Shoppe by 18.1% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,410 shares of the specialty retailer’s stock worth $110,000 after purchasing an additional 1,440 shares during the period. Mason Street Advisors LLC raised its position in Vitamin Shoppe by 7.0% in the 1st quarter. Mason Street Advisors LLC now owns 5,569 shares of the specialty retailer’s stock worth $112,000 after purchasing an additional 366 shares during the period. Wolverine Trading LLC purchased a new position in Vitamin Shoppe in the 2nd quarter worth $131,000. Finally, UBS Asset Management Americas Inc. raised its position in Vitamin Shoppe by 17,041.4% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 11,999 shares of the specialty retailer’s stock worth $140,000 after purchasing an additional 11,929 shares during the period. Institutional investors own 96.86% of the company’s stock.
Vitamin Shoppe Company Profile
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.